Publication Name	World Journal of Gastroenterology
Manuscript ID	5818
Country	United States

Received	2013-09-27 06:52
Peer-Review Started	2013-09-27 11:57
To Make the First Decision	2013-10-14 21:10
Return for Revision	2013-12-02 10:06
Revised	2014-02-08 05:14
Second Decision	2014-02-20 15:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-02-20 16:05
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-04-23 10:19
Publish the Manuscript Online	2014-05-14 10:58

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand?
Manuscript Source	Invited Manuscript
All Author List	Masato Fujiki, Federico Aucejo, Minsig Choi and Richard Kim
Funding Agency and Grant Number
Corresponding Author	Richard Kim, MD, Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Drive FOB-2, Tampa, FL 33612, United States. richard.kim@moffitt.org
Key Words	Bridging therapy; Neo-adjuvant therapy; Locoregional therapy; Intermediate stage; Living donor liver transplantation; Ablation; Transarterial chemotherapy; Transarterial radioembolization; External beam radiotherapy
Core Tip	Transarterial chemoembolization (TACE) and radiofrequency ablation are effective in down-staging intermediate staged hepatocellular carcinoma (HCC) to fulfill Milan criteria for liver transplantation (LT). New techniques using drug eluting beads-TACE, transarterial radioembolization and stereotactic radiation therapy have shown promising results in the treatment for advanced HCC over conventional TACE. In current practice, use of multimodality approach, taking advantage of the benefits of different locoregional therapy for HCC have been adopted as down-staging and bridging therapy for LT. Use of mandatory observation period prior to LT can exclude highly aggressive liver cancer that might not benefit from LT.
Publish Date	2014-05-14 10:58
Citation	Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand? World J Gastroenterol 2014; 20(18): 5308-5319
URL	http://www.wjgnet.com/1007-9327/full/v20/i18/5308.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i18.5308

Full Article (PDF)	WJG-20-5308.pdf
Full Article (Word)	WJG-20-5308.doc
Manuscript File	5818-Review.doc
Answering Reviewers	5818-Answering reviewers.pdf
Copyright License Agreement	5818-Copyright assignment.pdf
Peer-review Report	5818-Peer reviews.pdf
Scientific Editor Work List	5818-Scientific editor work list.doc